MedTrace Logo

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

NCT01333423 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-06-26

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.

Conditions

Interventions

DRUG

Liposomal Doxorubicin

40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.

DRUG

Seliciclib

Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Stacy Moulder, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01333423 on ClinicalTrials.gov